Geoffrey Whitley
Family · Charlestown, MANPI 1083994404
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (38.9%), consulting fees and speaking fees — rather than concentrated in one kind of arrangement. 24 manufacturers reported payments, led by Axsome Therapeutics, Inc. at 43.6% of the total. Among family clinicians in MA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,159 payments — averaging $56.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Axsome Therapeutics, Inc.$29K
- Johnson & Johnson$14K
- Alkermes, Inc.$4K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$4K
- Takeda Pharmaceuticals U.S.A., Inc.$2K
- Sunovion Pharmaceuticals Inc.$2K
- plus $10K from 18 others
What the payments were for
- Consulting fees$18,78929%
- Speaking & faculty fees$17,64827%
- Travel & lodging$3,4295%
- Food & beverage$25,51539%
- Education$2050%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Axsome Therapeutics, Inc. | 82 | $28,610 |
| Johnson & Johnson | 82 | $14,101 |
| Alkermes, Inc. | 64 | $4,101 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 161 | $3,984 |
| Takeda Pharmaceuticals U.S.A., Inc. | 117 | $2,390 |
| Sunovion Pharmaceuticals Inc. | 108 | $2,262 |
| Neurocrine Biosciences, Inc. | 82 | $2,160 |
| Corium, LLC | 120 | $1,900 |
| Lundbeck LLC | 118 | $1,651 |
| Otsuka America Pharmaceutical, Inc. | 89 | $1,485 |
| Supernus Pharmaceuticals, Inc. | 60 | $1,183 |
| Teva Pharmaceuticals USA, Inc. | 43 | $854 |
| E.r. Squibb & Sons, L.L.C. | 8 | $273 |
| Biohaven Pharmaceutical Holding Company Ltd. | 5 | $155 |
| Tris Pharma Inc | 5 | $95 |
| Avanir Pharmaceuticals, Inc. | 4 | $93 |
| Harmony Biosciences LLC | 1 | $63 |
| Vanda Pharmaceuticals Inc. | 2 | $58 |
| Collegium Pharmaceutical, Inc. | 2 | $38 |
| Idorsia Pharmaceuticals US Inc | 2 | $30 |
| Indivior Inc. | 1 | $30 |
| Alfasigma USA, Inc. | 1 | $26 |
| Ironshore Pharmaceuticals Inc. | 1 | $24 |
| Eisai Inc. | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$65,586 in reported general payments places this provider in the 95th percentile of 2,320 family providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 19 | $174,059 |
| CaplytaLumateperone Tosylate | 94 | $157,910 |
| RexultiBrexpiprazole | 104 | $156,316 |
| Austedo XrDeutetrabenazine | 14 | $130,896 |
| AustedoDeutetrabenazine | 14 | $105,595 |
| AuvelityDextromethorphan Hbr/Bupropion | 66 | $89,743 |
| TrintellixVortioxetine Hydrobromide | 110 | $54,252 |
| LybalviOlanzapine/Samidorphan Malate | 19 | $32,580 |
| VyvanseLisdexamfetamine Dimesylate | 70 | $26,098 |
| Aripiprazole | 162 | $24,035 |
| Abilify MaintenaAripiprazole | 11 | $23,919 |
| Effexor XrVenlafaxine Hcl | 19 | $12,200 |
| Lurasidone Hcl | 58 | $11,345 |
| Adderall XrDextroamphetamine/Amphetamine | 27 | $10,958 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 393 | $8,185 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo Xr, Austedo | $854 | $236,49128 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti, Abilify Maintena | $1,485 | $180,235115 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $2,160 | $174,05919 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $3,984 | $157,91094 claims |
| Axsome Therapeutics, Inc.Auvelity | $28,610 | $89,74366 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $2,390 | $80,351180 claims |
| Alkermes, Inc.Lybalvi | $4,101 | $32,58019 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,320 family providers in Massachusetts.
Other family in Charlestown
- Paul GouldLakeville$343K
- Brittany MurrayBoston$141K
- Jennifer FlemingLawrence$80K
- Naomi AmudalaBoston$79K
- Katherine O'BrienWinthrop$58K
- Kristy SmithActon$57K
- Leslie StefanowiczDartmouth$56K
- Marissa CasilloFoxborough$31K
- Rochelle NazarianDanvers$31K
- Yelena KiselWorcester$25K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.